InvestorsHub Logo
Post# of 175562
Next 10
Followers 71
Posts 3860
Boards Moderated 0
Alias Born 03/20/2010

Re: None

Sunday, 01/27/2019 9:33:34 PM

Sunday, January 27, 2019 9:33:34 PM

Post# of 175562
Vivos Inc. has obtained an exclusive license to eight (8) patents related to RadioGel™ device technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and Vivos announced in February 2011. The Agreement grants Vivos an exclusive license to make, have made, use and sell RadioGel™ as a device. Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 particles and the polymer gel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News